Banner year: US FDA approved 39 new drugs/biologics in 2012
This article was originally published in SRA
While the US Food and Drug Administration did not break any records in 2012 with approvals of new molecular entities (NMEs) and new biologics, the agency was on fire - surpassing by nine the number of nods it gave to novel medicines a year earlier and far outpacing the 21 approved in 2010.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.